Results 41 to 50 of about 359,969 (343)

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

Annals of the Rheumatic Diseases, 2015
The objective of this systematic literature review was to determine the association between cardiovascular events (CVEs) and antirheumatic drugs in rheumatoid arthritis (RA) and psoriatic arthritis (PsA)/psoriasis (Pso).
C. Roubille, V. Richer, T. Starnino, C. McCourt, Alexandra Mcfarlane, P. Fleming, S. Siu, J. Kraft, C. Lynde, J. Pope, W. Gulliver, S. Keeling, J. Dutz, L. Bessette, R. Bissonnette, B. Haraoui   +15 more
semanticscholar   +1 more source

Histidine catabolism is a major determinant of methotrexate sensitivity

Nature, 2018
The chemotherapeutic drug methotrexate inhibits the enzyme dihydrofolate reductase1, which generates tetrahydrofolate, an essential cofactor in nucleotide synthesis2. Depletion of tetrahydrofolate causes cell death by suppressing DNA and RNA production3.
Naama Kanarek, Heather R. Keys, J. Cantor, C. Lewis, Sze Ham Chan, Tenzin Kunchok, Monther Abu-Remaileh, Elizaveta Freinkman, Lawrence D. Schweitzer, D. Sabatini   +9 more
semanticscholar   +1 more source

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.

JAMA dermatology, 2020
Importance Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children.
I. M. Bronckers, A. Paller, D. West, I. Lara‐Corrales, M. Tollefson, W. Tom, M. Hogeling, Leah T. Belazarian, C. Zachariae, E. Mahé, E. Siegfried, U. Blume-Peytavi, Z. Szalai, R. Vleugels, K. Holland, R. Murphy, L. Puig, K. Cordoro, J. Lambert, A. Alexopoulos, U. Mrowietz, W. Kievit, M. Seyger   +22 more
semanticscholar   +1 more source

Primary CNS Lymphoma [PDF]

, 2014
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is an aggressive malignancy that exhibits unique biological features and characteristic clinical behaviour, with overall long-term survival rates of around 20–40 %.
Cwynarski, K, Fox, CP, Phillips, EH
core   +1 more source

NMDAR‐Antibody Encephalitis Diagnosed With Primary Central Nervous System Lymphoma: A Case Series

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT N‐methyl‐D‐aspartate receptor‐antibody encephalitis (NMDAR encephalitis) is one of the most common forms of autoimmune encephalitis, with a paraneoplastic relationship described in approximately 38%. Primary central nervous system lymphoma (PCNSL) is a rare hematologic malignancy that is not often considered as the underlying neoplasm in this ...
Soo Hyun Ahn, Cynthea Prima, Tae Min Kim, Soon‐Tae Lee, Kon Chu   +4 more
wiley   +1 more source

Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis

Pediatric Rheumatology Online Journal, 2017
Background Methotrexate is the most commonly used disease modifying antirheumatic drug in the treatment of juvenile idiopathic arthritis and can be effective in controlling disease in many patients.
Sonja Falvey, Lauren Shipman, Norman Ilowite, Timothy Beukelman   +3 more
doaj   +1 more source

Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine [PDF]

, 2012
Introduction: The idiopathic inflammatory myopathies are rare diseases for which data regarding the natural history, response to therapies and factors affecting mortality are needed.
Crofford, Leslie J., MacDonald, Paul M., Phillips, Kristine, Schiopu, Elena, Somers, Emily C.   +4 more
core   +3 more sources

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara, Kathleen Bush, M. Elaine Husni, Soumya M. Reddy, Jose U. Scher, Ethan Craig, Joelle Koplin, Jessica A. Walsh, Alexis Ogdie   +8 more
wiley   +1 more source

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

Arthritis & Rheumatology, 2017
We undertook this phase III study to evaluate baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis (RA) who had received no ...
R. Fleischmann, M. Schiff, D. M. van der Heijde, C. Ramos-Remus, A. Spindler, M. Stanislav, C. Zerbini, Sirel Gurbuz, C. Dickson, S. de Bono, D. Schlichting, S. Beattie, W. Kuo, Terence Rooney, W. Macias, T. Takeuchi   +15 more
semanticscholar   +1 more source

Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis. [PDF]

, 2019
Background Long-term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long-term corticosteroid-sparing immunosuppression in CS is unknown.
Benn, Bryan S, De Marco, Teresa, Gerstenfeld, Edward P, Hsia, Henry H, Janmohamed, Munir, Klein, Liviu, Koth, Laura L, Lee, Byron K, Moss, Joshua D, Murray, Tyler O, Pampaloni, Miguel H, Parwani, Purvi, Petek, Bradley J, Rosenthal, David G, Scheinman, Melvin M, Selby, Van, Vedantham, Vasanth, Zikherman, Julie   +17 more
core